Generic alternative to EpiPen released amid allergy treatment shortage

Sandoz, a generics and biosimilar unit of Novartis, will make its generic epinephrine shots immediately available for sale in U.S. retail pharmacies as a shortage of Mylan's lifesaving allergy treatment EpiPen drags on.

Sandoz announced June 9 the retail launch of Symjepi, a single-dose, pre-filled syringe and device that is an alternative to EpiPen. 

"Patients and healthcare professionals are trying to navigate this critical shortage of self-injectable epinephrine products, which is why Sandoz is immediately making Symjepi available in adult and pediatric doses to patients at their local pharmacies," said Carol Lynch, president of Sandoz.

In January, Sandoz launched Symjepi shots for use in hospitals.

More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation's 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars